Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices
August 15th 2024Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.
Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice
August 15th 2024A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.